ASH 2022 Conference Coverage
N

ASH 2022 High-Grade B-Cell Lymphoma, Not Otherwise Specified: CNS Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series

By ASH 2022 Conference Coverage FEATURING Narendranath Epperla
By ASH 2022 Conference Coverage FEATURING Narendranath Epperla
0 views
December 22, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Recommended

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
22:09
Scripps Health

New Updates in Frontline DLBCL

Feat. L. Nastoupil
27:47
Indy Hematology Review

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Feat. S. Smith
08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou
35:27
Louisville Hematology Highlights

Updates on Management of DLBCL

Feat. J. Leonard
10:04
Tara Graff

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

04:04
Wojciech Jurczak

Polatuzumab Vedotin for 1L DLBCL: Results From the POLARIX Trial

22:11
SOHO Brazil 2024

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

Feat. A. Zelenetz
17:07
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Comparative Review of Toxicities and Their…

Feat. M. Minnema
35:24
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: Aggressive B-Cell Lymphomas

Feat. G. Nowakowski
08:01
Georg Lenz

Treatment Landscape in 1L DLBCL: Polatuzumab Vedotin as SoC

34:36
MyCancerHaven

Frontline DLBCL Treatment Approaches

Feat. R. Vij, H. Cherng
62:02
UChicago Medicine

New Treatment Strategies in DLBCL

Feat. L. Sehn
29:26
Massachusetts General Hospital Cancer Center

Practice-Changing Updates in DLBCL and HL

Feat. J. Erika Haydu
15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
04:29
Juan Pablo Alderuccio

Polatuzumab Vedotin in 1L DLBCL: Perspectives on the POLARIX Trial

17:21
Daniel Addison

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

30:07
Dipenkumar Modi

Current Management of DLBCL From Frontline to Relapsed Disease

09:27
ASH 2022 Conference Coverage

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

Feat. M. McMullin
33:48
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: B-Cell Lymphoma

Feat. L. Nastoupil